Bio-Techne (NASDAQ: TECH) reported Q4 EPS of $1.09, $0.10 better than the analyst estimate of $0.99. Revenue for the quarter came in at $156.6 million versus the consensus estimate of $150.12 million.

Fourth Quarter and Full Year FY2017 Snapshot

• Fourth quarter organic revenue increased by 8% (16% reported) to $156.6 million. Fiscal year 2017 organic revenue grew 6% (13% reported) to $563.0 million.
• GAAP fully diluted earnings per share (EPS) for fourth quarter increased 12% to $0.77. Full year GAAP fully diluted EPS was $2.06.
• Delivered adjusted earnings per share (EPS) of $1.09 in the fourth quarter and $3.72 for the full year. This represents an increase of 18% and 3%, respectively, over the prior year, with foreign currency exchange headwinds negatively impacting results by $0.01 or 1% in the fourth quarter and $0.05 or 1% for the full year.
• Cash Flow from Operations, excluding acquisition-related earn-outs for the year, was a record $57.0 million for the quarter and $158.0 million for the full year.
• Protein Platforms segment delivered 24% organic growth in Q4, led by the Biologics (iCE), Simple Plex (Ella), and Single Cell Western platforms.
• Advanced Cell Diagnostics' (ACD) RNAscope is being well-received in the Diagnostics and CDx markets, in addition to the RUO market, with revenues once again growing over 50% on a stand-alone basis.

For earnings history and earnings-related data on Bio-Techne (TECH) click here.